 |
|
|
|
FDA808a-2
Multiple organ tumor tissue array with adjacent normal human organs, including TNM, clinical stage and pathology grade, 72 cases/72 cores, replacing FDA808-2
|
|
| Microarray Panel: | Multiple organ tumor tissue microarray with adjacent normal human organs, containing 54 cases of tumor of varieties of organ tissue, plus 18 cases of 6 types of adjacent normal organs, single core per case |
| Cores: | 72 |
|
| Cases: | 72 |
| Layout: | 9 cols × 8 rows |
| Core Diameter: | 1.5 mm |
| Thickness: | 5 µm | | Quality Control: | Anti-Actin confirmed | | Applications: | Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page. |
| Notes: | Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure. |
*Tissue Microarray Slide Types:
- Unstained: unstained
paraffin
tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Microarray Panel Display  | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
| A |
|
|
|
|
|
|
|
|
|
|
| B |
|
|
|
|
|
|
|
|
|
|
| C |
|
|
|
|
|
|
|
|
|
|
| D |
|
|
|
|
|
|
|
|
|
|
| E |
|
|
|
|
|
|
|
|
|
|
| F |
|
|
|
|
|
|
|
|
|
|
| G |
|
|
|
|
|
|
|
|
|
|
| H |
|
|
|
|
|
|
|
|
|
 |
|
| Legend: | Abd - Abdominal cavity,
Bla - Bladder,
Bon - Bone,
Bre - Breast,
Car - Cardiac pericardium,
Cer - Cerebrum,
Col - Colon,
Eso - Esophagus,
Int - Intestine,
Kid - Kidney,
Liv - Liver,
Lun - Lung,
Lym - Lymph node,
Med - Mediastinum,
Ner - Nerve,
Ova - Ovary,
Pan - Pancreas,
Pel - Pelvic cavity,
Pro - Prostate,
Rec - Rectum,
Ret - Retroperitoneum,
Ske - Skeletal muscle,
Ski - Skin,
Smo - Smooth muscle,
Sof - Soft tissue,
Spl - Spleen,
Sto - Stomach,
Str - Striated muscle,
Tes - Testis,
Thr - Thyroid,
Ton - Tongue,
Ute - Uterine cervix
 - Benign tumor,
 - Benign tumor,
 - Malignant tumor,
 - Malignant tumor,
 - Malignant tumor (stage I),
 - Malignant tumor (stage IB G1),
 - Malignant tumor (stage II),
 - Malignant tumor (stage IIB),
 - Malignant tumor (stage IIB G2),
 - Malignant tumor (stage III),
 - Malignant tumor (stage IIIA),
 - Malignant tumor (stage IIIB G3),
 - Malignant tumor (stage IIIa),
 - Malignant tumor (stage IIa),
 - Malignant tumor (stage IIb),
 - Malignant tumor (stage IIb G2),
 - Malignant tumor (stage IV),
 - Malignant tumor (stage Ib),
 - NAT,
 - Normal tissue
|
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Stage |
TNM |
Type † |
|
A1 |
1 |
F |
21 |
Uterus |
Normal endometrium tissue |
– |
– |
– |
Normal |
|
A2 |
2 |
F |
21 |
Uterus |
Normal endometrium tissue (smooth muscle and blood vessel) |
– |
– |
– |
Normal |
|
A3 |
3 |
F |
18 |
Uterus |
Normal endometrium tissue |
– |
– |
– |
Normal |
|
A4 |
4 |
F |
32 |
Uterine cervix |
Cancer adjacent normal cervical canals tissue (chronic inflammation of fibrous tissue and blood vessel) |
– |
– |
– |
NAT |
|
A5 |
5 |
F |
50 |
Uterine cervix |
Cancer adjacent normal cervical canals tissue |
– |
– |
– |
NAT |
|
A6 |
6 |
F |
72 |
Uterine cervix |
Cancer adjacent normal cervix tissue |
– |
– |
– |
NAT |
|
A7 |
7 |
F |
25 |
Skeletal muscle |
Normal skeletal muscle tissue |
– |
– |
– |
Normal |
|
A8 |
8 |
M |
38 |
Skeletal muscle |
Normal skeletal muscle tissue |
– |
– |
– |
Normal |
|
A9 |
9 |
M |
47 |
Tongue |
Normal thyroid gland tissue |
– |
– |
– |
Normal |
|
B1 |
10 |
F |
42 |
Skin |
Normal skin tissue |
– |
– |
– |
Normal |
|
B2 |
11 |
M |
37 |
Skin |
Normal skin tissue |
– |
– |
– |
Normal |
|
B3 |
12 |
F |
18 |
Skin |
Normal skin tissue |
– |
– |
– |
Normal |
|
B4 |
13 |
F |
15 |
Nerve |
Normal peripheral nerve tissue |
– |
– |
– |
Normal |
|
B5 |
14 |
F |
18 |
Nerve |
Normal peripheral nerve tissue |
– |
– |
– |
Normal |
|
B6 |
15 |
M |
47 |
Nerve |
Normal peripheral nerve tissue |
– |
– |
– |
Normal |
|
B7 |
16 |
M |
50 |
Cardiac pericardium |
Normal mesothelial tissue |
– |
– |
– |
Normal |
|
B8 |
17 |
F |
27 |
Cardiac pericardium |
Normal mesothelial tissue |
– |
– |
– |
Normal |
|
B9 |
18 |
M |
22 |
Lung |
Normal lung and pleura tissue |
– |
– |
– |
Normal |
|
C1 |
19 |
F |
61 |
Cerebrum |
Glioblastoma with necrosis (sparse) |
– |
– |
– |
Malignant |
|
C2 |
20 |
F |
65 |
Cerebrum |
Atypical meningioma |
– |
– |
– |
Malignant |
|
C3 |
21 |
F |
15 |
Cerebrum |
Malignant ependymoma |
– |
– |
– |
Malignant |
|
C4 |
22 |
F |
39 |
Cerebrum |
Oligodendroglioma |
2 |
– |
– |
Malignant |
|
C5 |
23 |
F |
63 |
Ovary |
Serous adenocarcinoma |
3 |
II |
T2N0M0 |
Malignant |
|
C6 |
24 |
F |
29 |
Ovary |
Adenocarcinoma |
3 |
III |
T3N0M0 |
Malignant |
|
C7 |
25 |
F |
12 |
Pancreas |
Islet cell tumor |
– |
– |
– |
Malignant |
|
C8 |
26 |
M |
64 |
Pancreas |
Adenocarcinoma |
3 |
III |
T3N0M0 |
Malignant |
|
C9 |
27 |
M |
32 |
Testis |
Seminoma |
– |
I |
T1N0M0 |
Malignant |
|
D1 |
28 |
M |
30 |
Testis |
Embryonal carcinoma |
– |
I |
T2N0M0 |
Malignant |
|
D2 |
29 |
F |
33 |
Thyroid |
Medullary carcinoma |
– |
II |
T3N0M0 |
Malignant |
|
D3 |
30 |
F |
19 |
Thyroid |
Papillary carcinoma |
– |
III |
T3N1M0 |
Malignant |
|
D4 |
31 |
F |
48 |
Breast |
Intraductal carcinoma with early infiltrate |
– |
IIIa |
T3N1M0 |
Malignant |
|
D5 |
32 |
F |
43 |
Breast |
Invasive ductal carcinoma |
2 |
IIa |
T2N0M0 |
Malignant |
|
D6 |
33 |
F |
58 |
Breast |
Invasive ductal carcinoma |
2 |
IIb |
T2N1M0 |
Malignant |
|
D7 |
34 |
M |
21 |
Spleen |
Diffuse B-cell lymphoma |
– |
– |
– |
Malignant |
|
D8 |
35 |
M |
61 |
Lung |
Small cell undifferentiated carcinoma |
– |
I |
T2N0M0 |
Malignant |
|
D9 |
36 |
M |
66 |
Lung |
Squamous cell carcinoma |
3 |
I |
T2N0M0 |
Malignant |
|
E1 |
37 |
F |
75 |
Lung |
Adenocarcinoma |
2 |
II |
T2N1M0 |
Malignant |
|
E2 |
38 |
M |
60 |
Esophagus |
Squamous cell carcinoma (esophagus tissue) |
– |
IIa |
T2N0M0 |
Malignant |
|
E3 |
39 |
M |
63 |
Esophagus |
Adenocarcinoma |
3 |
IIa |
T3N0M0 |
Malignant |
|
E4 |
40 |
F |
73 |
Stomach |
Mucinous adenocarcinoma |
3 |
– |
– |
Malignant |
|
E5 |
41 |
M |
30 |
Intestine |
Adenocarcinoma |
2 |
III |
T3N1M0 |
Malignant |
|
E6 |
42 |
F |
71 |
Intestine |
Malignant interstitialoma |
– |
IIb G2 |
T2N0M0 |
Malignant |
|
E7 |
43 |
F |
72 |
Colon |
Adenocarcinoma |
2 |
IIB |
T4N0M0 |
Malignant |
|
E8 |
44 |
M |
54 |
Abdominal cavity |
Interstitialoma |
– |
IIb G2 |
T2N0M0 |
Malignant |
|
E9 |
45 |
M |
36 |
Rectum |
Adenocarcinoma |
3 |
I |
T2N0M0 |
Malignant |
|
F1 |
46 |
F |
63 |
Rectum |
Moderate malignant interstitialoma |
– |
IIB G2 |
T2N0M0 |
Malignant |
|
F2 |
47 |
F |
55 |
Liver |
Hepatocellular carcinoma |
1 |
IIIA |
T3N0M0 |
Malignant |
|
F3 |
48 |
F |
17 |
Liver |
Hepatoblastoma |
– |
– |
– |
Malignant |
|
F4 |
49 |
M |
60 |
Kidney |
Clear cell carcinoma |
2 |
II |
T2N0M0 |
Malignant |
|
F5 |
50 |
M |
70 |
Prostate |
Adenocarcinoma (Gleason grade:5 Gleason score:4+5) |
3 |
IV |
T3N1M0 |
Malignant |
|
F6 |
51 |
M |
77 |
Prostate |
Adenocarcinoma (Gleason grade:2 Gleason score:3+4) |
2 |
II |
T2N0M0 |
Malignant |
|
F7 |
52 |
F |
33 |
Uterus |
Leiomyoma |
– |
Ib G1 |
T2N0M0 |
Benign |
|
F8 |
53 |
F |
55 |
Uterus |
Adenocarcinoma endometrium |
1 |
IIa |
T2aN0M0 |
Malignant |
|
F9 |
54 |
F |
39 |
Uterus |
Clear cell carcinoma of endometrium |
|
IIb |
T2bN0M0 |
Malignant |
|
G1 |
55 |
F |
36 |
Uterine cervix |
Squamous cell carcinoma |
3 |
Ib |
T1bN0M0 |
Malignant |
|
G2 |
56 |
F |
49 |
Uterine cervix |
Squamous cell carcinoma |
3 |
II |
T2N0M0 |
Malignant |
|
G3 |
57 |
F |
20 |
Striated muscle |
Embryonal rhabdomyosarcom of left leg |
– |
IIB G2 |
T1aN0M0 |
Malignant |
|
G4 |
58 |
F |
70 |
Rectum |
Malignant melanoma |
– |
II |
T4N0M0 |
Malignant |
|
G5 |
59 |
M |
61 |
Skin |
Basal cell carcinoma of head |
– |
IIa |
T2N0M0 |
Malignant |
|
G6 |
60 |
M |
46 |
Skin |
Squamous cell carcinoma of left chest wall |
2 |
II |
T3N0M0 |
Malignant |
|
G7 |
61 |
M |
59 |
Soft tissue |
Neurofibroma |
– |
– |
– |
Benign |
|
G8 |
62 |
F |
3 |
Retroperitoneum |
Neuroblastoma (sparse) |
– |
– |
– |
Malignant |
|
G9 |
63 |
M |
60 |
Abdominal cavity |
Malignant mesothelioma |
– |
IIB G2 |
T2N0M0 |
Malignant |
|
H1 |
64 |
M |
49 |
Mediastinum |
Diffuse B-cell lymphoma of lymph node |
– |
– |
– |
Malignant |
|
H2 |
65 |
F |
50 |
Lymph node |
Diffuse B cell lymphoma of right thigh |
– |
– |
– |
Malignant |
|
H3 |
66 |
M |
53 |
Lymph node |
Hodgkin's lymphoma |
– |
– |
– |
Malignant |
|
H4 |
67 |
F |
19 |
Pelvic cavity |
Anaplastic large cell lymphoma |
– |
– |
– |
Malignant |
|
H5 |
68 |
M |
76 |
Bladder |
Transitional cell carcinoma |
3 |
II |
T3aN0M0 |
Malignant |
|
H6 |
69 |
M |
62 |
Bladder |
Low grade malignant leiomyosarcoma |
– |
IB G1 |
T2bN0M0 |
Malignant |
|
H7 |
70 |
F |
7 |
Bone |
Osteosarcoma of right inferior extremity femur |
– |
IB G1 |
T2N0M0 |
Malignant |
|
H8 |
71 |
F |
48 |
Retroperitoneum |
Spindle cell rhabdomyosarcoma |
– |
IIB G2 |
T2N0M0 |
Malignant |
|
H9 |
72 |
F |
60 |
Smooth muscle |
Moderate malignant leiomyosarcoma of left buttock |
– |
IIIB G3 |
T2bN0M0 |
Malignant |
|
–
|
– |
M |
42 |
Adrenal gland |
Pheochromocytoma (tissue marker) |
– |
|
|
Malignant |
† For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
TNM grading:
T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis
|
|
